UROonco23 meeting report: GU cancer updates

UROonco23 meeting report: GU cancer updates

The first ever UROonco meeting (UROonco23) was held from 30 June to 2 July in Gothenburg, Sweden, and marked a successful collaboration among multiple onco-urology groups.

Prof. Morgan Rouprêt (FR), chair of ESOU and a member of the UROonco23 steering committee, stated, “We are pleased to inform you that the meeting was a resounding success, with nearly 700 delegates and faculty in attendance. The sponsoring activities supported the meeting well, with nine exhibition booths onsite. UROonco23 proved to be a great way for European-based urologists to get the latest research and updates from the global spectrum of GU cancers urological gatherings such as ESMO, ASCO GU, AUA and ASCO.”

Featuring an extensive scientific programme, UROonco23 included 11 plenary sessions, significant international trial updates, rapid-fire presentations, interactive roundtable sessions, hands-on training, guidelines updates, and the STEPS programme for young urologists.

Several editorial board members from the UROONCO Educational Platform interviewed key presenters to attain highlights of the significant trial results showcased at UROonco23:

Prostate cancer

Dr. Giancarlo Marra (IT) talks to Dr. Alberto Bossi (IT) about the PEACE-1 study results. This is a phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel, with or without local radiotherapy, with or without abiraterone acetate and prednisone, in metastatic hormone naïve prostate cancer patients. Watch the interview.

Prof. Alberto Briganti (IT) shares details with Dr. Marra on the management of men with negative conventional imaging (cN0M0) but pathologically node positive prostate cancer lymphadenectomy performed at the time of radical cystectomy for muscle invasive
urothelial cancer. Watch the interview.

Bladder cancer

Prof. Seth Lerner (US) shares an update on the SWOG S1011 trial with Dr. Laura Mertens (NL). This phase III surgical trial evaluates the benefit of a “standard” versus “extended” lymphadenectomy performed at the time of radical cystectomy for muscle invasive urothelial cancer. Watch the interview.

Dr. Yohann Loriot (FR) elaborates on the phase 3 THOR trial results with Dr. Benjamin Pradere (FR). The trial assesses the efficacy of erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor (FGFR) alterations. Watch the interview.

Assoc. Prof. Alessia Cimadamore (IT) talks about fibroblast growth factor receptor (FGFR) screening with Dr. Benjamin Pradere (FR). They discuss in what setting it is useful, particularly for assisting in bladder-sparing treatment. Watch the interview.

Dr. Carmen Mir (ES) discusses the new intravesical drug delivery systems for bladder cancer, particularly the TAR device, with Dr. Benjamin Pradere (FR). Watch the interview.

Kidney cancer

Dr. Raquibul Hannan (US) details the latest trends in stereotactic body radiotherapy (SBRT) for kidney cancer with Dr. Mir. Watch the interview.

Dr. Hannan received the ‘European Urology Oncology Best Paper Award’ for his work, “Phase II trial of stereotactive ablative radiation for oligoprogressive metastatic kidney cancer.

The UROonco23 meeting success underscored the importance in advancing the management and treatment of genitourinary cancers via collaborative learning and information sharing between onco urology groups.


Save the date!
UROonco24 will take place in Budapest, Hungary, from 20 to 22 June, 2024 (Thursday – Saturday). For more information, visit www.uroonco24.org